Business
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
Results demonstrate the use of selective inhibitors of multiple key cytokines as an effective strategy in treating autoimmune diseases driven by T and NK
About this update from Equillium, Inc.
[{"type":"text","content":"\nResults demonstrate the use of selective inhibitors of multiple key cytokines as an effective strategy in treating autoimmune diseases driven by T and NK cells\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced data presented at the annual La Jolla Immunology Conference. The research highlights the potential for multi-cytokine inhibitors such as EQ101 and EQ102, as potentially effective strategies for the treatment of certain autoimmune diseases.\n\n“The complexity of cytokine signaling to regulate immune homeostasis presents unique drug development challenges when treating disease,” said Steve Connelly, chief scientific officer at Equillium. “EQ101 and EQ102 are both first-in-class multi-cytokine inhibitors that provide selective targeting of biological redundancy and synergy at the receptor level, which has significant advantages over other approaches, including JAK inhibition. The results shown here demonstrate the effects of EQ101 and EQ102 in the modulation of important biology relevant to several autoimmune and inflammatory diseases. We look forward to initiating a Phase 2 clinical study of EQ101 in subjects with alopecia areata, and a Phase 1 first-in-human study of EQ102 in normal healthy volunteers – as well as celiac patients – both by the end of this year.”\n\nTitle: EQ101 and EQ102, selective multi-cytokine antagonists, inhibit cytotoxic T cell and NK activity\nPoster: I29\nAuthor: Phoi Tiet, Senior Research Associate, Equillium, Inc., et al.\n\nThe presentation highlights important roles of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells in the pathogenesis of various autoimmune and inflammatory diseases, and their activity being driven by multiple cytokines. For this research, human peripheral blood mononuclear cells (PBMCs) were stimulated with anti-CD3 and CD28 antibodies, rested overnight, labeled with a proliferation dye, treated with EQ101 or EQ102, and stimulated with IL-15 for 72 hours, then analyzed for surface activation markers by flow cytometry. Treatment of PBMCs with EQ101 or EQ102 resulted in an approximate 50% decrease in proliferation of CD4 T cell subsets, and an approximate 40% decrease...